Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models
- PMID: 15589579
- DOI: 10.1016/j.ygyno.2004.09.025
Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models
Abstract
Objective: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
Methods: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal. Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types. After 1-2 months, grafts were retrieved for comparison with original tissues. Hematoxylin and eosin (H&E) and immunohistochemical staining was carried out using tissue micro-arrays and CEA, B72.3, WT-1, OC125, keratin, inhibin, CK7, CK20, Cam5.2, and MIB-1 as markers.
Results: Tumor tissue engraftment rate was > 95%. Comparison of donor and post-graft tissues showed highly similar histopathological features; 91 +/- 5% concordance in immunostaining indicated major preservation of immunophenotypes in the xenografts for 30-60 days. There was a small, but significant, increase in MIB-1 proliferative index in xenografts compared to original specimens.
Conclusions: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues. The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms. Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.
Similar articles
-
Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.Clin Cancer Res. 2006 Jul 1;12(13):4043-54. doi: 10.1158/1078-0432.CCR-06-0252. Clin Cancer Res. 2006. PMID: 16818704
-
Effects of IL-12 on human ovarian tumors engrafted into SCID mice.Gynecol Oncol. 1999 Feb;72(2):154-60. doi: 10.1006/gyno.1998.5239. Gynecol Oncol. 1999. PMID: 10021294
-
Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice.Int J Urol. 2006 Jan;13(1):47-57. doi: 10.1111/j.1442-2042.2006.01220.x. Int J Urol. 2006. PMID: 16448432
-
Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.Mod Pathol. 2005 Feb;18 Suppl 2:S61-79. doi: 10.1038/modpathol.3800310. Mod Pathol. 2005. PMID: 15761467 Review.
-
The subrenal capsule assay for chemosensitivity testing of tumors. A review.Zentralbl Gynakol. 1988;110(16):989-96. Zentralbl Gynakol. 1988. PMID: 3055756 Review.
Cited by
-
Optical imaging of gastric cancer with near-infrared heptamethine carbocyanine fluorescence dyes.Oncotarget. 2016 Aug 30;7(35):57277-57289. doi: 10.18632/oncotarget.10031. Oncotarget. 2016. PMID: 27329598 Free PMC article.
-
Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.Am J Pathol. 2009 Oct;175(4):1638-52. doi: 10.2353/ajpath.2009.090384. Epub 2009 Sep 3. Am J Pathol. 2009. PMID: 19729488 Free PMC article.
-
Next generation patient-derived prostate cancer xenograft models.Asian J Androl. 2014 May-Jun;16(3):407-12. doi: 10.4103/1008-682X.125394. Asian J Androl. 2014. PMID: 24589467 Free PMC article.
-
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.J Pathol. 2011 Oct;225(2):212-21. doi: 10.1002/path.2929. Epub 2011 Jun 27. J Pathol. 2011. PMID: 21710693 Free PMC article.
-
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896656 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials